| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 139.51 | 79.1% |
| Total Income | 139.51 | 79.1% |
| Expenditure | 154.94 | 2.5% |
| PBT | -8.51 | 101.6% |
| Net Profit | -9.49 | 101.8% |
| OPM | -11.06% | 88.41pp |
| NPM | -6.80% | 84.62pp |
| EPS | -0.06 | 101.9% |
Novavax Reports Q1 2026 Revenue of $140 Million
06 May 2026 · 6 May, 5:32 pm
Summary
Novavax announced its financial results and operational highlights for the first quarter ended March 31, 2026. Total revenue for the first quarter of 2026 was $140 million, a 79% decrease compared to $667 million in the same period in 2025, which included $603 million of non-cash sales revenue. The company signed a new Matrix-M license with Pfizer and secured four additional MTAs with large pharmaceutical and biotech companies. Novavax is reiterating its full year 2026 financial guidance for combined R&D and SG&A expenses and expects to achieve adjusted total revenue of between $230 million and $270 million.
Key Highlights
- 1
Novavax reported total revenue of $140 million in the first quarter of 2026.
- 2
A license agreement with Pfizer was announced in January for non-exclusive use of Matrix-M® in two infectious disease areas.
- 3
Novavax signed a new MTA with a top 10 leading pharmaceutical company to explore Matrix-M in multiple oncology and infectious disease targets in April.
- 4
In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseases.
- 5
Sanofi announced positive results from the Phase 4 COMPARE study, reinforcing Nuvaxovid’s well established and differentiated reactogenicity profile.
- 6
Novavax’s C. difficile vaccine candidate prioritized with potential to enter the clinic as early as 2027.
- 7
The company reiterates its 2026 Revenue Framework and Combined R&D and SG&A expense guidance.
Management Comments
John C. Jacobs
Novavax continued to make significant progress executing our corporate strategy which is comprised of partnering our technology, capital-efficient R&D innovation and a lean operating platform. In 2026, we signed a new, Matrix-M license with Pfizer for up to two vaccine candidates and secured four additional MTAs with a growing list of large pharmaceutical and innovative biotech companies. With these agreements in place, our partners have the right to evaluate Matrix in over 30 unique fields of experimentation targeting more than 50% of the projected over $100B market for infectious disease and oncology vaccines and immuno-therapeutics. In addition, Novavax continued to advance our own R&D efforts with the selection of our C. difficile vaccine candidate as our next potential asset to advance to the clinic as early as 2027.”
Informational and educational content only. Not investment advice.